124 related articles for article (PubMed ID: 3567865)
1. The role of adjunctive immunotherapy in superficial bladder cancer.
Fujita K
Cancer; 1987 Jun; 59(12):2027-30. PubMed ID: 3567865
[TBL] [Abstract][Full Text] [Related]
2. Immunological evaluation of a streptococcal preparation (OK-432) in treatment of bladder carcinoma.
Kagawa S; Ogura K; Kurokawa K; Uyama K
J Urol; 1979 Oct; 122(4):467-70. PubMed ID: 480487
[TBL] [Abstract][Full Text] [Related]
3. [An experience of OK-432 intradermal administration in superficial bladder tumors].
Tsujihashi H; Akiyama T; Kurita T; Iguchi M; Uejima S; Kataoka K; Minakata S; Kitagawa M; Sangen H
Hinyokika Kiyo; 1988 Dec; 34(12):2111-4. PubMed ID: 3239522
[TBL] [Abstract][Full Text] [Related]
4. Antigenic relationship between streptococcal preparation OK-432 and tumors and its effect on immunotherapy with OK-432 in patients with superficial bladder tumor.
Fujioka T; Aoki H; Yoshida M; Ohhori T; Kubo T
Urol Int; 1989; 44(4):198-204. PubMed ID: 2477930
[TBL] [Abstract][Full Text] [Related]
5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
6. [Local immunotherapy with streptococcal preparation, OK-432 in superficial bladder tumors, and common antigens between OK-432 and the tumor].
Fujioka T; Shiraishi M; Tanji S; Koike H; Suzuki K; Kumagai K; Aoki H; Sakuma Y; Ohhori T; Kubo T
Hinyokika Kiyo; 1989 Feb; 35(2):253-7. PubMed ID: 2735236
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of tumors of the urinary bladder with so-called immunopotentiators].
Tsujimura S; Kato J; Ueda K; Ohtaguro K
Hinyokika Kiyo; 1983 Jan; 29(1):9-15. PubMed ID: 6677093
[TBL] [Abstract][Full Text] [Related]
8. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
[TBL] [Abstract][Full Text] [Related]
10. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.
Kurth KH; Bouffioux C; Sylvester R; van der Meijden AP; Oosterlinck W; Brausi M
Eur Urol; 2000; 37 Suppl 3():1-9. PubMed ID: 10828681
[TBL] [Abstract][Full Text] [Related]
11. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of streptococcal preparation (OK-432) local injection in patients with urinary bladder carcinoma.
Nishio S; Izeki T; Wada S; Morikawa Y; Yasumoto R; Maekawa M
Osaka City Med J; 1980; 26(1):47-59. PubMed ID: 7267092
[No Abstract] [Full Text] [Related]
13. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
[TBL] [Abstract][Full Text] [Related]
14. [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L
Urologe A; 1994 Mar; 33(2):138-43. PubMed ID: 8178408
[TBL] [Abstract][Full Text] [Related]
15. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy.
Agarwal A; Agrawal U; Verma S; Mohanty NK; Saxena S
Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):348-56. PubMed ID: 20105083
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group.
Cancer; 1987 Nov; 60(10):2394-402. PubMed ID: 2889522
[TBL] [Abstract][Full Text] [Related]
17. Histological changes caused by intralesional injection of a streptococcal preparation into bladder cancer.
Fujita K
Cancer Detect Prev; 1988; 11(3-6):397-403. PubMed ID: 3292046
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study].
Kälble T; Möhring K; Ikinger U; Riedasch G; Staehler G
Urologe A; 1991 Mar; 30(2):118-21. PubMed ID: 2058066
[TBL] [Abstract][Full Text] [Related]
19. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
[TBL] [Abstract][Full Text] [Related]
20. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Uhlig A; Strauss A; Seif Amir Hosseini A; Lotz J; Trojan L; Schmid M; Uhlig J
Eur Urol Focus; 2018 Dec; 4(6):924-936. PubMed ID: 28888813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
